On July 31, Eximia Research announced that it acquired Tidewater Clinical Research, a contract research organization (CRO) that is based in Norfolk, Virginia.
Since 1994, Tidewater Clinical Research has been at the forefront of women’s health research in the Hampton Roads/Eastern Virginia region. With a substantial patient database and a strong network of investigators, Tidewater has conducted numerous clinical trials that have significantly advanced medical knowledge and patient care.
Eximia is a multi-site, multi-therapeutic, clinical research site network serving pharmaceutical, biotech companies and CROs and providing Phase I-IV research services across a diverse range of therapeutic indications, including neurology, psychiatry, dermatology, vaccines, gastroenterology and metabolic disorders with access to underrepresented patient populations. In October 2023, VSS Capital Partners became an owner.
This strategic development unites Tidewater’s long standing expertise in women’s health and ophthalmology with Eximia’s extensive clinical trial experience and resources. The addition of Tidewater’s 97,000 patients brings Eximia’s total patient volume up to nearly one million patients nationwide. The financial terms were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the 18th CRO transaction of the year. Throughout all of 2023, there were 44 CRO transactions.
